In fiscal 2026, which ended Apr 30, 2026, HeartSciences Inc. reported revenue of $4,319, down 0.7% from the year before. It recorded a net loss of $9.1 million. The operating loss came to $8.4 million, an operating margin of -194787.4%. Across the 4 fiscal years shown, revenue shrank from $5,150 in fiscal 2023 to $4,319 in fiscal 2026, about 5.7% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2027
Jul 31, 2026
|
FY 2026
Apr 30, 2026
|
FY 2025
Apr 30, 2025
|
FY 2024
Apr 30, 2024
|
FY 2023
Apr 30, 2023
|
|---|---|---|---|---|---|
| Revenue |
—
|
0
-0.7%
|
0
-76.6%
|
0
+261.2%
|
0
|
| Cost of revenue |
—
|
0
-6.0%
|
0
-69.1%
|
0
+117.5%
|
0
|
| Gross profit |
—
|
0
+3.3%
|
0
-80.3%
|
0
+431.8%
|
0
|
| Research and development |
—
|
3
-35.3%
|
4
+52.4%
|
3
+17.0%
|
2
|
| Selling, general and administrative |
—
|
6
+40.5%
|
4
+15.4%
|
3
-5.9%
|
4
|
| Operating expenses |
—
|
8
+0.7%
|
8
+32.2%
|
6
+3.3%
|
6
|
| Operating income |
—
|
-8
-0.7%
|
-8
-32.5%
|
-6
-3.2%
|
-6
|
| Income tax |
—
|
0
|
—
|
—
|
—
|
| Net income |
—
|
-9
-4.3%
|
-9
-32.7%
|
-7
-3.9%
|
-6
|
| Basic EPS |
—
|
-3.48
+62.7%
|
-9.34
+50.2%
|
-18.74
+76.6%
|
-80.00
|
| Diluted EPS |
—
|
—
|
-9.34
+50.2%
|
-18.74
+76.6%
|
-80.00
|
| Weighted average shares, basic |
—
|
3
+179.8%
|
1
+166.2%
|
0
+343.4%
|
0
|
| Weighted average shares, diluted |
—
|
—
|
1
+166.2%
|
0
+343.4%
|
0
|
| Other measures | |||||
| Depreciation and amortization |
—
|
0
-26.1%
|
0
+34.8%
|
0
+3.6%
|
0
|
| EBITDA |
—
|
-8
-0.8%
|
-8
-32.4%
|
-6
-3.2%
|
-6
|
| Interest coverage |
—
|
-11.17x
|
-16.69x
|
—
|
—
|
| Margins | |||||
| Gross margin |
—
|
59.06%
|
56.78%
|
67.31%
|
45.71%
|
| Operating margin |
—
|
-194,787.38%
|
-192,013.13%
|
-33,901.99%
|
-118,698.33%
|
| Profit margin |
—
|
-211,666.47%
|
-201,499.52%
|
-35,511.87%
|
-123,384.27%
|
| EBITDA margin |
—
|
-194,143.92%
|
-191,148.78%
|
-33,752.03%
|
-118,175.71%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Finance Services (SIC 6199)
- Listed as
- HSCS (Nasdaq), HSCSW (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- TX
- Headquarters
- Southlake, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1468492
- Former names
- Heart Test Laboratories, Inc. (until Oct 18, 2024)
Other Finance Services companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.